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A variety of immunoregulatory signals to effector T cells from monocytes, macrophages and regula-
tory T cells act through cyclic adenosine monophosphate. In the effector T cell, the protein kinase A
(PKA) type I isoenzyme localizes to lipid rafts during T cell activation and modulates directly the
proximal events that take place after engagement of the T cell receptor. The most proximal target
for PKA phosphorylation is C-terminal Src kinase (Csk), which initiates a negative signal pathway
that ﬁne-tunes the T cell activation process. The A kinase anchoring protein Ezrin colocalizes PKA
and Csk by forming a supramolecular signaling complex consisting of PKA, Ezrin, Ezrin/radixin/moe-
sin (ERM) binding protein of 50 kDa (EBP50), phosphoprotein associated with glycosphingolipid-
enriched membrane microdomains (GEMs) (PAG) and Csk.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Engagement of the T cell receptor/CD3 (TCR/CD3) complex can
lead to a wide range of responses spanning from anergy and apop-
tosis to T cell activation with cytokine production, cytotoxic activ-
ity and proliferation. An optimal immune response requires the
antigen to be presented to the T cell by an antigen presenting cell
(APC) (the primary stimulus) in conjunction with a costimulus (the
secondary stimulus, e.g. CD28 or IL-2). Engagement of the TCR/CD3
complex elicits a signaling cascade in the T cell that involves
numerous signaling molecules including protein tyrosine kinaseschemical Societies. Published by E
ase anchoring protein; APC,
phosphate; Cbp, Csk binding
dixin/moesin (ERM) binding
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r tyrosine-based activation
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associated with glycosphin-
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kén).(PTKs), protein tyrosine phosphatases (PTPs), G proteins, guanine
nucleotide exchange factors (GEFs) and adaptor molecules [1,2].
The ﬁrst event is activation of the Src family PTKs Lck and FynT,
which subsequently leads to phosphorylation of the immunore-
ceptor tyrosine-based activation motifs (ITAMs) present in the
f, e, d and c subunits of the TCR/CD3 complex [3,4]. The phosphor-
ylation of the ITAMs promotes recruitment and subsequent activa-
tion of the Syk-PTK f-chain associated protein of 70 kDa (ZAP-70).
The activation of the Src PTKs and ZAP-70 leads to phosphorylation
of adaptor molecules and recruitment of enzymes facilitating the
activation of downstream signaling pathways [1]. These events
take place in specialized microdomains of the plasma membrane
termed lipid rafts that have a high constituency of cholesterol
and glycosphingolipids [5]. The activation cascade culminates in
gene transcription, cytoskeletal rearrangement, cytokine produc-
tion and proliferation.
Activation of cyclic adenosine 30,50-monophosphate (cAMP) sig-
naling involves binding of an extracellular ligand to a G protein-
coupled receptor (GPCR) through which G proteins regulate one
of several isoforms of adenylyl cyclase (AC), leading to generation
of cAMP [6]. Although other effectors of cAMP have been identiﬁed
[7,8], the most versatile effector system is protein kinase A (PKA).
Ligand-induced changes in cAMP concentration vary in duration,
amplitude and localization in the cell. Spatiotemporal organization
of cAMP microdomains is accomplished through coupled control oflsevier B.V. All rights reserved.
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terases (PDEs), a subset of the superfamily of more than 10 classes
of cyclic nucleotide PDEs that degrade cAMP and cGMP [6,9]. Dif-
ferent PKA isoenzymes with distinct biochemical properties and
cell-speciﬁc expression contribute to cell and organ speciﬁcity
(for review and references see [10]). A kinase anchoring proteins
(AKAPs) target PKA to speciﬁc substrates and distinct subcellular
compartments providing spatial and temporal speciﬁcity for medi-
ation of biological effects induced through the cAMP–PKA pathway
(for review and references see [10,11]). AKAPs also serve as scaffold
proteins that assemble PKA together with signal proteins such as
phosphatases and cAMP-speciﬁc PDEs as well as components of
other signaling pathways into multiprotein signaling complexes
that serve as crossroads for different signaling pathways [12]. Tar-
geting of PKA and integration of a wide repertoire of proteins in-
volved in signal transduction into complex signal networks
further increase the speciﬁcity required for the precise regulation
of numerous cellular and physiologic processes. The cAMP–PKA
pathway is strongly involved in the regulation and modulation of
immune responses and is the most potent and acute inhibitor of
activation of lymphocytes. The mechanisms of cAMP-mediated
immunomodulation are discussed in more detail below.2. Triggering of the T cell signaling cascade
The primary event leading to activation of T cells is the trigger-
ing of their antigen-speciﬁc TCR by a processed antigenic peptide
presented by a major histocompatibility complex (MHC) class II
molecule on the surface of an APC or by a MHC class I molecule
on a target cell. This event triggers several signal transduction
pathways that involve second messengers, protein kinases, protein
phosphatases and other enzymes and key intermediates [2,13,14].
The signaling cascade culminates with the induction of gene tran-
scription, leading to cytokine production and proliferation.
It is generally agreed that a key initiating event in T cell activa-
tion by antigen is the increased phosphorylation of ITAM tyrosines
in the TCR subunits by the Src family kinases Lck and FynT (and
perhaps c-Yes) [2]. However, exactly how the TCR couples antigen
recognition to this phosphorylation event is not clear. Proposed
models include (i) Juxtaposition of Lck to the TCR mediated by
CD4 or CD8 [15,16], (ii) increased local concentration of kinases
and their substrates following receptor oligomerization and lipid
raft coalescence [17–21], and (iii) the active exclusion of C-termi-
nal Src kinase (Csk) and PTPases [22]. These mechanisms are not
mutually exclusive, and probably all operate in concert, but despite
the understanding of these three parallel mechanisms the very ini-
tial molecular events still appear not to be fully elucidated. Fur-
thermore, proteins involved in proximal TCR signaling are
localized in lipid rafts, membrane microdomains enriched in cho-
lesterol and sphingolipids and coalescence in such membrane
microdomains that enrich populations of signalling molecules ap-
pears important although this issue has been debated recently
[23–25].
Phosphorylated ITAMs in the CD3 f chain serve to recruit the
PTK ZAP-70, which subsequently phosphorylates linker for activa-
tion of T cells (LAT), Src homology 2 (SH2) domain-containing leu-
kocyte protein of 76 kDa (SLP-76) and phospholipase Cc1 (PLCc1).
The signaling cascade continues with the recruitment of (catalytic
and non-catalytic) proteins such as growth factor receptor bound
protein-2 (Grb2), Grb-related adaptor downstream of Shc (Gads),
the p85 subunit of phosphatidylinositol 3 kinase (PI3K) and Nck
to LAT, which propagates intracellular signaling pathways involv-
ing activation of Ras, protein kinase C (PKC), Ca2+ mobilization, cal-
cineurin and polymerization of the actin cytoskeleton. A complete
immune response ﬁnally leads to activation of the transcriptionfactors nuclear factor jB (NF-jB) and nuclear factor of activated
T cells (NFAT) initiating cytokine secretion and T cell proliferation
[26–29].3. Suppression of Src family PTKs by Csk
As Lck and FynT both play a pivotal role in the ﬁrst signal events
resulting from triggering of the TCR, it is not surprising that they
are tightly regulated by multiple mechanisms (reviewed in
[19,22]). Similar regulatory mechanisms are also present in other
cell types that express different members of the Src family PTKs.
An important mode of regulation of Src family PTKs is by phos-
phorylation at a conserved tyrosine residue within the catalytic do-
main, Y394 in Lck and Y417 in FynT. It is generally believed that Src
family PTKs autophosphorylate at this site, presumably in trans.
Both Lck and FynT (as well as other Src family PTKs) are nega-
tively regulated by phosphorylation at a conserved C-terminal reg-
ulatory tyrosine residue, Y505 in Lck and Y528 in FynT [30,31].
When phosphorylated, the tail tyrosine binds to the SH2 domain
of the same kinase molecule, thereby forcing the catalytic SH1 do-
main into an inactive conformation [32]. Analysis of the crystal
structures of C-terminally phosphorylated Src [33] and Hck [34]
also revealed that the Src homology 3 (SH3) domain is important
for stabilizing the kinase domain in the inactive conformation by
binding to a region in the linker between the SH2 domain and
the kinase domain. In T cell lines, approximately half of all Lck mol-
ecules are phosphorylated at Y505 [35], but changes in the phos-
phorylation status of Y505 have not been observed during T cell
activation. Instead, the phosphotyrosine content of Lck increases
after T cell activation due to phosphorylation of Y394 [36]. This
may suggest that the activity of Lck in TCR signaling is not depen-
dent on acute dephosphorylation at Y505 and could implicate a yet
unknown, high afﬁninty ligand for the Lck SH2 domain that binds
to and displaces the intrinsic Lck C-terminus permitting Lck activa-
tion without dephosphorylation of Y505.
The PTK responsible for the suppressive phosphorylation of Lck
at Y505 and FynT at Y528 is Csk, a widely expressed 50-kDa en-
zyme [37,38]. At present, Csk is the only PTK known to have this
speciﬁcity. The ﬁnding that disruption of the csk gene is lethal
[39,40] and that cells recovered from the early embryos contain
greatly activated Src family PTKs, suggests that no other gene can
fully compensate for the loss of csk during embryogenesis. Further-
more, both inducible knockouts and mature T cells with acute
elimination of Csk exhibit increased Src family kinase activation
and are hyperresponsive to T cell stimuli [41,42]. Nevertheless, it
is possible that the other Csk family member Csk homologous ki-
nase (CHK) also functioning as a negative regulatory kinase of
the Src family kinases (reviewed in [43]), may participate in the
suppression of Src family PTKs in other cell types.
Consistent with a negative role of Csk in the regulation of Src
family PTKs, overexpression of Csk in T cells leads to a marked
reduction of TCR-induced tyrosine phosphorylation and interleu-
kin 2 (IL-2) production. The activity of Csk require both its SH2-
and SH3 domains and is further enhanced by targeting Csk to the
plasma membrane [44]. One explanation for the requirement of
the SH3 domain is that Csk speciﬁcally associates through its
SH3 domain with the PEST (motif enriched in proline, glutamic
acid, serine, and threonine residues)-enriched tyrosine phospha-
tase (PEP) and its human ortholog lymphoid tyrosine phosphatase
(LYP) [45], which has been implicated in autoimmune diseases
[46]. Thus, the targeting of Csk to the plasma membrane may not
only increase its access to Src-related PTKs but also serve to recruit
PEP/LYP to the plasma membrane and improve its activity leading
to dephosphorylation of membrane-associated proteins (e.g. Lck or
FynT).
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Csk has a similar intramolecular organization to that of the Src
family PTKs with SH3-, SH2- and kinase domains, but differs from
the Src kinases by the lack of the C-terminal regulatory tyrosine
and autophosphorylation sites as well as the N-terminal lipid mod-
iﬁcation sequence that targets members of the Src family PTKs to
membranes. For that reason, it has for some time been unclear
how this ubiquitously expressed cytosolic kinase effectively regu-
lates the membrane associated Src kinases Lck and FynT even
though Csk has been shown to be localized to sites of Src activity
in ﬁbroblasts [47]. The cloning and characterization of a trans-
membrane adaptor protein associated with lipid rafts, Csk binding
protein (Cbp)/PAG, has revealed new insight into Csk-mediated
regulation of the Src kinases [48,49]. Cbp/PAG binds to the SH2 do-
main of Csk. It is ubiquitously expressed and likely interacts with
actin ﬁlaments through an Ezrin/radixin/moesin (ERM) binding
protein of 50 kDa (EBP50)–ERM protein complex [50,51]. Further-
more, Cbp/PAG has a palmitoylation site and a cytoplasmic tail
with 10 sites for tyrosine phosphorylation that is phosphorylated
primarily by FynT in T cells [52] whereas Cbp/PAG dephosphoryl-
ation is mediated by CD45 or PTPa [53,54].
Csk, FynT and EBP50 are reproducibly found to interact with
Cbp/PAG in vivo and Y317 (Y314 in mouse and rat) is identiﬁed
as the binding site for the SH2 domain of Csk, while FynT interacts
by coordinated binding through its SH3 and SH2 domains [55].
Interestingly, stimulation of T cells with antibodies towards CD3
alone or in combination with CD28 induces dephosphorylation of
Cbp/PAG resulting in decreased Csk content in lipid rafts [20,48].
It has further been demonstrated that Csk association with Cbp/
PAG is transient and corresponds with the kinetics of T cell activa-
tion [20]. Dephosphorylation of Cbp/PAG and dissociation of the
Cbp/PAG–Csk complex after TCR engagement is preceded by Cbp/
PAG–FynT dissociation, suggesting that the latter may trigger the
loss of the Cbp/PAG–Csk interaction in activated T cells [56].
Overexpression of kinase-deﬁcient Csk that displaces endoge-
nous Csk from lipid rafts has stimulatory effects on f chain phos-
phorylation and IL-2 promoter activation both in resting T cells
and after TCR triggering [20]. Therefore, tonic suppression of Lck
kinase activity in rafts by Csk seems to set the threshold for TCR
signaling and appears important in order to avoid improper TCR
signaling and T cell activation. Regulation of Csk kinase activity
in lipid rafts may therefore be crucial to prevent aberrant immune
activation and autoimmunity. Although not completely under-
stood, T cell activation requires transient dissociation of Csk from
lipid rafts, allowing Lck to become activated and to perform its cat-
alytic functions, which provides an elegant mechanism for modu-
lation of proximal TCR signaling [20]. However, Cbp/PAG knock
out studies indicate that Cbp/PAG is dispensable both for embryo-
genesis and T cell development and function and suggest that Cbp/
PAG may be redundant and that other Csk binding proteins may
exist in rafts [57,58].
Concomitant with the activation of Lck and dissociation of Csk
from lipid rafts, Csk associates with a 72-kDa protein via its SH2
domain [59]. This protein was recently identiﬁed as G3BP, a phos-
photyrosine-containing protein reported to bind the SH3 domain
of Ras GTPase-activating protein, which seems to serve to seques-
ter Csk outside lipid rafts [60]. The formation of a complex of Csk
and G3BP in T cells occurs within a time course that is similar to
that of Csk dissociation from Cbp/PAG upon TCR stimulation.
In addition, one major aspect of unraveling the processes con-
trolling the initiation of TCR signaling would undoubtedly be the
identiﬁcation and characterization of the PTPs responsible for
dephosphorylating Cbp/PAG. In addition to CD45 [61,62], the PTPShp2 appears to be involved in the phosphorylation status of
Cbp/PAG [63]. C-terminal tyrosines are hyperphosphorylated in
Shp2 deﬁcient cells which leads to decreased tyrosine phosphory-
lation in substrates of the Src family kinases. Shp2 regulates both
the activation of Src family kinases and the activation of the Ras/
Erk signaling pathway.
5. Regulation of cAMP-levels in T cells
The common and versatile second messenger cAMP controls
numerous cellular processes and is known to be a potent inhibitor
of T cell proliferation and cytokine production [64,65]. The cAMP–
PKA signaling pathway in T cells is initiated by binding of prosta-
glandin E2 (PGE2) and other extracellular ligands such as catechol-
amines, serotonin, adenosine and histamine to GPCRs, activation of
AC and the subsequent generation of cAMP from ATP [66]. Endoge-
nous cAMP levels in T cells are also inﬂuenced by othermechanisms
such as those described below involving regulatory T cells.
Human regulatory T cells comprise 5–10% of the peripheral
CD4+ T cell population [67] and are functionally characterized by
their ability to suppress effector T cells in addition to having an
essential role in maintaining immunological tolerance [68]. This
subset of CD4+ T cells has been under intense research the last dec-
ade due to its role in various clinical conditions such as autoim-
mune disease, cancer and chronic viral infections. Regulatory T
cells can further be subdivided into naturally occurring regulatory
T cells that are derived in the thymus and adaptive or peripherally
induced regulatory T cells that are developed from naïve T cells in
the periphery during immune activation [69]. The role of cAMP in
induction of regulatory T cells and regulatory T cell-mediated sup-
pression is getting increasing attention (reviewed in [70]). Natu-
rally occurring regulatory T cells have been shown to have high
cAMP levels and to mediate their suppressive function by transfer-
ring cAMP to effector T cells through gap junctions [71]. The high
cAMP levels in regulatory T cells can at least partly be explained
by the FOXP3-dependent downregulation of phosphodiesterase
3B (PDE3B) [72]. Furthermore, the ecto-enzymes CD39 and CD73
expressed on naturally occurring regulatory T cells may degrade
ATP and catalyze the generation of adenosine which acts via the
adenosine A2a receptor on activated effector T cells, thereby sup-
pressing their function by intracellular production of cAMP [73].
In addition, continuous antigen exposure to T cells leads to gener-
ation of adaptive regulatory T cells [74]. Adaptive regulatory T cells
express cyclooxygenase 2 (COX-2), leading to secretion of PGE2.
PGE2 stimulates FOXP3 expression in regulatory T cells in addition
to inhibit effector T cell function through activation of the cAMP–
PKA–Csk signaling pathway [75]. The different mechanisms affect-
ing effector T cells described above are schematically summarized
in Fig. 1. In the context of high cAMP in regulatory T cells it is also
interesting to note that cAMP levels may in part be controlled by a
microRNA, miR-142-3p, that inhibits expression of AC9 in effector
T cells but not in regulatory T cells where FoxP3 counteracts this
effect and releases AC9 from inhibition [76].
The spatiotemporal regulation of intracellular cAMP gradients is
a result of the combined action of ACs and PDEs, which provide the
sole route of cAMP degradation [77,78]. The importance of PDE ac-
tion in T cells is evident [79–81], not least from experiments show-
ing that PDE inhibition augments the increase in cAMP caused by T
cell activation [82]. Not only are the cAMP speciﬁc PDE 4 family of
enzymes (PDE4) [78] the main contributors to PDE-mediated deg-
radation of cAMP in T cells [80], but PDE4 selective inhibitors exert
a major component of the anti-inﬂammatory action through atten-
uation of T cell immune function [83,84]. Thus, one might expect
that PDE4 activity would serve to promote T cell activity by reduc-
ing cAMP levels in the appropriate intracellular compartment. It is
Fig. 1. Schematic model of cAMP-mediated induction of Treg cells and suppression of effector T cells. Naturally occurring Tregs have high cAMP levels and mediate their
suppressive function by transferring cAMP to responder T cells through gap junctions. In addition, the ecto-enzymes CD39 and CD73 expressed on naturally occurring Tregs
degrade ATP/ADP and catalyze the generation of adenosine, acting via the adenosine A2a receptor on activated effector T cells and thereby suppressing their function by
intracellular production of cAMP. Furthermore, continuous activation of T cells results in generation of adaptive Tregs that express COX-2, leading to PGE2 production.
Increased PGE2 levels stimulate further FOXP3 expression in Treg cells in addition to inhibiting effector T cell function. Finally, T cell inhibition and induction of FOXP3 due to
PGE2 secretion can also be a result of LPS-activated monocytes.
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activity and cAMP production [64,85], and it appears that TCR
stimulation elicits a negative feed-back loop acting through cAMP.
However, it has been shown that cAMP production elicited by TCR
engagement is ablated upon CD28 costimulation [86]. CD28 costi-
mulation recruits PDE4 to the lipid raft fraction which would serve
to decrease cAMP and release the cell from inhibition [86]. Recruit-
ment of PDE4 to lipid rafts is accompanied by recruitment of the
scaffold protein b-arrestin (for review see, [87]), which in various
other cell types has been shown to play an important role in
uncoupling the receptor-mediated stimulation of Gs [88] and
allowing the receptor-mediated recruitment of PDE4 isoforms
[89,90].
The CD28 co-receptor plays a central role in T cell activation
in vivo. Although engagement of the TCR provides the necessary
scaffolding from which TCR signaling is propagated, CD28 func-
tions as an ampliﬁer necessary to promote optimal IL-2 production
and clonal expansion and to prevent anergy and cell death. The
CD28-mediated signals are transmitted via a short intracellular
stretch in the receptor containing conserved motifs important for
docking of several signaling proteins [91]. Phosphorylation of a
tyrosine residue (Y173) in the conserved YMNM motif by Lck and
Fyn is key to efﬁcient signal transduction [92]. This generates a
docking site for the SH2-domain of p85, the regulatory subunit of
phosphatidylinositol 3-kinase (PI3K) [93]. The C-terminal PXXP
motif is another important binding site recognized by both Src
family kinases and Grb2 [94]. It has been somewhat controversial
whether CD28 alone can induce PI3K activity. However, phosphor-
ylation of the PKB substrate glycogen synthase kinase 3 (GSK3)
upon CD28 stimulation has been observed [95,96], demonstrating
that PI3K is indeed activated upon CD28 stimulation alone. Thus,
we examined how b-arrestin and PDE4 levels in T cell lipid raftswere affected by inhibition of either SFKs or PI3K using PP2 and
LY294002, respectively. Strikingly, CD28-induced recruitment of
b-arrestin in primary T cells was abolished both upon Lck/Fyn-
and PI3K-inhibition. Furthermore, PDE4 activity in raft fractions
from T cells pre-treated with the PI3K inhibitor prior to CD28 stim-
ulation was reduced below basal levels and no increase in PDE4
activity was observed upon CD28 ligation [97]. Taken together,
these data suggest a novel mechanism whereby PI3K can regulate
cAMP degradation through recruitment of a PDE4/b-arrestin com-
plex to lipid rafts.
Activation of PI3K results in rapid phosphatidylinositol 3,4,5-
trisphosphate (PIP3) generation in the inner leaﬂet of the plasma
membrane and recruitment of proteins containing a specialized
lipid-binding moiety called the pleckstrin homology (PH) domain.
Thus, PIP3 controls both activity and sub-cellular localization of a
broad range of signal transduction molecules [98]. Vav-1, Itk and
PKB are three PH-containing proteins that have been implicated
both downstream of PI3K signaling and in TCR/CD28 co-stimula-
tion [99]. We recently demonstrated that b-arrestin interacts
with PIP3 in an activation-dependent fashion although b-arrestin
does not possess a PH domain [97]. We therefore hypothesized
the presence of a PH domain-containing interaction partner in-
side the complex that confers binding to PIP3 and can mediate
the translocation of the PDE4D/b-arrestin complex upon TCR/
CD28 co-stimulation [97]. Interestingly, PKB was shown to be re-
cruited to lipid rafts concurrently with b-arrestin in TCR/CD28
co-stimulated T cells. In addition, we found that PKB co-immuno-
precipitated with b-arrestin in TCR/CD28 co-stimulated T cells,
and it was further demonstrated that PKB, b-arrestin and PDE4
through deﬁned contact areas indeed form a tri-molecular inter-
action where b-arrestin interacts directly with both PKB and
PDE4 [97].
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Cyclic AMP and PKA regulate immune function at multiple lev-
els. Possible targets for PKA phosphorylation that can modulate an
immune response are the transcription factors cAMP responsive
element binding protein (CREB), NFAT and NF-jB, and upstream
targets like HePTP, Ras, Raf, MAP/ERK kinase (MEK), mitogen acti-
vated protein kinase (MAPK), PLCc1/2, PLCb, Csk and RhoA (re-
viewed in [100]). However, based on studies with selective
agonists, activation of PKA type I (RIa2C2) has been shown to be
necessary and sufﬁcient for mediating inhibition of TCR-induced
T cell activation by cAMP [101]. Similarly, PKA type I negatively
regulates activation of B cells through the B cell antigen receptor
[102] and NK cell cytotoxicity elicited through speciﬁc NK cell
receptors [103]. Although PKA can modulate TCR signaling at mul-
tiple levels (reviewed in [100]), the observed inhibitory effects of
cAMP on TCR-induced f chain phosphorylation point to an impor-
tant role for Csk, which is the most upstream PKA target reported
so far. PKA phosphorylates S364 in Csk, and thereby induces a 2- to
4-fold increase in phosphotransferase activity of Csk in lipid rafts
of T cells [104] (Fig. 2).
Analyses of lipid raft puriﬁcations from normal resting T cells
for the presence of different subunits of PKA reveal that both the
catalytic subunits Ca and Cb2 [105] and the regulatory subunit
RIa (but no RII subunits) are constitutively associated with lipid
rafts [104]. This suggests that the colocalization of PKA type I
and the TCR in capped T cells [101] occurs in lipid rafts and that
there are mechanisms for speciﬁc targeting of PKA type I to these
areas that involve interaction with an AKAP. The AKAP that targets
PKA type I to lipid rafts has recently been identiﬁed as Ezrin [106].
Other AKAPs such as AKAP79, AKAP95, AKAP149, AKAP220,
AKAP450, AKAP-KL, WAVE and MTG16b have also been identiﬁed
in T cells [106,107], but have yet to be identiﬁed in lipid rafts.
Ezrin is a 78-kDa protein belonging to the ERM family of proteins
that plays structural and regulatory roles in the assembly and stabil-
ization of specialized plasma membrane domains by linking micro-
ﬁlaments to the membrane. ERM proteins have a highly
homologous N-terminal band four-point-one ERM (FERM) domain
that binds directly to a number of transmembrane proteins includ-
ing CD44 andCD43 [108,109] in addition to indirect binding to other
membrane proteins via scaffold proteins like EBP50. The actin cyto-
skeleton interaction is via the C-terminus [110]. Most of Ezrins
interactions are dependent on conformational activation of themol-Fig. 2. Inhibition of T cell activation by cAMP is mediated by a PKA type I-Ezrin–EBP50–Cb
TCR-induced T cell activation and thereby exerts important immunoregulatory functions
assembled in T cell lipid rafts and acting on the Src family kinase Lck. Ezrin serves t
transmembrane proteins like CD43 via its N-terminal FERM domain and with F-actin via
the proximity to its down-stream substrate Csk by forming a supramolecular signalingecule. In the dormant state, binding sites for interaction partners are
masked due to an intramolecular interaction between the FERM do-
main and the C-terminus. Upon phosphorylation of a C-terminal
threonine by PKC or Rho kinase, the intramolecular bond is released
and other interactions can occur [111]. Mapping studies of Ezrin re-
veal that the PKA RIa binding sequence is located in thea-helical re-
gion between the FERM domain and the C-terminus [106].
Functional evidence that PKA type I regulation of T cell re-
sponses is dependent on AKAP anchoring by Ezrin comes from
the observations that disruption of PKA type I binding to Ezrin
using and anchoring disruptor peptides Ht31 and RI anchoring dis-
ruptor (RIAD) or the peptides from the RI speciﬁer region (RISR) in
Ezrin displaces PKA type I from lipid rafts and releases the T cells
from cAMP-mediated inhibition of proliferation and IL-2 produc-
tion [106,112,113]. Furthermore, small interfering RNA (siRNA)-
mediated knockdown of Ezrin abrogated cAMP regulation of IL-2
secretion [106] whereas reconstitution with an siRNA resistant
wild type Ezrin, but not an Ezrin variant where the PKA binding do-
main had been mutated, reestablished the cAMP-regulation of IL-2
secretion [106,113]. Other possibilities for targeting of PKA type I
to its substrate Csk include anchoring of the PKA catalytic subunit
via the N terminal myristyl group into rafts, or via interactions
with a caveolin-like protein in T cell rafts, similar to the PKA Ca
interaction with caveolin in other cell types [114].
Studies of the organization of G proteins in the plasma mem-
brane have revealed that in addition to G proteins, lipid rafts also
contain AC activity [115]. In fact, a substantial fraction of the total
isoproterenol or forskolin-stimulated AC in S49 lymphoma cells is
present in these fractions, strongly suggesting that the receptor-G
protein and G protein-AC coupling occur in lipid rafts, and similar
data have been obtained for normal T cells and HEK293 cells [116].
This implies that the entire molecular machinery required for gen-
eration of cAMP and activation of PKA type I after engagement of
GPCRs is recruited to lipid rafts and organized in a receptor-G pro-
tein-AC-cAMP-PKA type I-Csk pathway scaffolded by Ezrin and
Cbp/PAG (Fig. 2).7. A supramolecular scaffold complex consisting of Ezrin, EBP50
and Cbp/PAG targets PKA type I to its substrate Csk
So far two different mechanisms are reported to regulate Csk
activity. PKA, through phosphorylation of S364, increases Csk ki-p/PAG–Csk supramolecular signaling complex in lipid rafts. In T cells, cAMP inhibits
through a receptor – G protein – AC – cAMP – PKA type I – Csk inhibitory pathway
o link the plasma membrane to the actin cytoskeleton through interaction with
its C-terminus. In T cell lipid rafts Ezrin functions as an AKAP, bringing PKA type I in
complex consisting of PKA type I, Ezrin, EBP50, Cbp/PAG and Csk.
2686 I. Cornez, K. Taskén / FEBS Letters 584 (2010) 2681–2688nase activity 2- to 4-fold leading to reduced Lck activity and f chain
phosphorylation. The other mechanism involves the adaptor mol-
ecule Cbp/PAG. Cbp/PAG recruits Csk to the site of action in lipid
rafts [48,49], and the interaction between Csk–SH2 and Cbp/PAG
through phosphorylated Y314 increases Csk activity [117]. Addi-
tion of either recombinant Cbp/PAG or peptides corresponding to
the Csk–SH2 binding site signiﬁcantly increased Csk kinase activity
towards a Src substrate in vitro. Thus, PKA phosphorylation of Csk
and Csk interaction with Cbp/PAG may act together in turning on
Csk activity, providing a powerful mechanism for terminating
activation through antigen receptors dependent on Src kinase sig-
naling (Fig. 2).
PKA RIa is located to lipid rafts [104]. Immunoﬂuorescense
studies of normal T cells reveal that a fraction of Ezrin colocalizes
with PKA RIa. Further, immunoprecipitation studies of the com-
plex consisting of Csk and Cbp/PAG demonstrate interaction with
both Ezrin and EBP50, and both Csk and the catalytic subunit of
PKA were present in immunoprecipitates of EBP50. Lastly, Csk
and the catalytic subunit of PKA coprecipitate indicating their asso-
ciation to the same scaffold proteins [106]. Together this demon-
strates formation of a lipid raft associated complex where Ezrin
brings PKA type I in the proximity to its down-stream substrate
Csk by forming a supramolecular signaling complex consisting of
PKA type I, Ezrin, EBP50, Cbp/PAG and Csk. Ezrin is bound via
CD43, CD44 or ICAMs to the plasma membrane [108,109,118]
and via its C-terminus to the actin cytoskeleton [110], and EBP50
links Ezrin to Cbp/PAG [50,51]. Thus, Ezrin positions PKA type I
in the proximity to its substrate Csk that is bound to Cbp/PAG
(Fig. 2). In support of this, it has earlier been shown that PKA phos-
phorylation of Csk occurs in lipid rafts [104] and that PKA phos-
phorylates the pool of Csk anchored to Cbp/PAG [85]. This,
together with the observations that downstream effector functions
modulated by the PKA-Csk pathway are released from cAMP inhi-
bition by knockdown of Ezrin and re-established by reconstitution
experiments argues that the PKA regulation of Csk is discretely
coordinated and spatiotemporally restricted to this supramolecu-
lar complex [106,113]. Interestingly, two recent papers have re-
ported the Cbp/PAG knockout showing that Cbp/PAG is
dispensable for T cell function [57,58]. However, while the two re-
ports agree on the lack of any effect of the Cbp/PAG null mutation
on T cell function, one report states that Cbp/PAG is dispensable
also for Csk localization and suggests that other adaptor proteins
might compensate [57] whereas the other report states that the
amount of Csk that localizes to lipid rafts is greatly reduced in
the absence of Cbp/PAG [58]. Anyhow, the possibility of redun-
dancy and the probable presence of other Csk anchoring proteins
open up the possibility that Csk is only regulated by PKA type I
in the context of the Ezrin–EBP50–Cbp/PAG scaffold and may es-
cape regulation by PKA if anchored elsewhere.8. Conclusions
The activities of both type I PKA and PDE4 seem to be important
for regulation of TCR-induced signaling and T cell function. Type I
PKA is activated by external stimuli such as PGE2 produced by reg-
ulatory T cells [75], monocytes [119], and adrenergic agonists as
well as by an intrinsic mechanism upon TCR stimulation both of
which induces cAMP production in lipid rafts and inhibits proximal
T cell signaling [86] (Fig. 1). However, CD28 co-stimulation leads to
recruitment of a PDE4/b-arrestin complex that releases cAMP inhi-
bition allowing a full T cell response to occur [97]. Finally, Ezrin is
the essential link between cytoskeletal F-actin and a lipid raft-
associated multiprotein complex including EBP50, Cbp/PAG, Csk
and PKA type I that negatively regulates immune responses upon
T cell activation (Fig. 2).Acknowledgments
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